Goldman Sachs
UBX

Goldman Sachs’s Unity Biotechnology UBX Stock Holding History

Goldman Sachs’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,066
Closed -$4K – 6280
2022
Q3 		$4K Buy
+1,066
New +$6.72K ﹤0.01% 6110
2022
Q2 		– Sell
-2,320
Closed -$26K – 6729
2022
Q1 		$26K Sell
2,320
-6,696
-74% -$75.1K ﹤0.01% 6378
2021
Q4 		$132K Buy
9,016
+4,848
+116% +$106K ﹤0.01% 6049
2021
Q3 		$125K Sell
4,168
-3,033
-42% -$107K ﹤0.01% 5872
2021
Q2 		$334K Buy
7,201
+247
+4% +$11.9K ﹤0.01% 5457
2021
Q1 		$418K Sell
6,954
-6,000
-46% -$409K ﹤0.01% 5247
2020
Q4 		$679K Buy
12,954
+7,096
+121% +$342K ﹤0.01% 4440
2020
Q3 		$203K Sell
5,858
-375
-6% -$23.7K ﹤0.01% 4908
2020
Q2 		$541K Sell
6,233
-290
-4% -$21.5K ﹤0.01% 4342
2020
Q1 		$379K Sell
6,523
-2,614
-29% -$165K ﹤0.01% 4376
2019
Q4 		$659K Buy
9,137
+1,554
+20% +$110K ﹤0.01% 4350
2019
Q3 		$463K Sell
7,583
-25,012
-77% -$1.77M ﹤0.01% 4486
2019
Q2 		$3.1M Sell
32,595
-1,415
-4% -$120K ﹤0.01% 3222
2019
Q1 		$2.76M Sell
34,010
-17,298
-34% -$1.96M ﹤0.01% 3394
2018
Q4 		$8.34M Buy
51,308
+1,641
+3% +$218K ﹤0.01% 2473
2018
Q3 		$8.09M Sell
49,667
-3,902
-7% -$642K ﹤0.01% 2613
2018
Q2 		$8.07M Buy
+53,569
New +$7.83M ﹤0.01% 2579

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs's UBX Position: Q4 2022 in Review

Goldman Sachs sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 1,066 shares — an estimated $4K sold.

Goldman Sachs first reported a position in UBX in Q2 2018 and held it in 17 quarters. The position peaked at $8.34M in Q4 2018. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • Goldman Sachs reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,066 Unity Biotechnology shares in Q4 2022, an estimated $4K.
  • Goldman Sachs first reported a position in Unity Biotechnology in Q2 2018 and held it in 17 quarters.
  • Goldman Sachs's Unity Biotechnology position peaked at $8.34M in Q4 2018.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.